Does ruxolitinib prolong the survival of patients with myelofibrosis?

A 73-year-old man was diagnosed with primary myelofibrosis (PMF) after the incidental discovery of abnormalities in a blood test performed for the control of diabetesmellitus. The patient was asymptomatic. The spleen was palpable at 6 cm below the left costal margin. Hemoglobin was 10.9 g/dL; white blood cell count was 13.2 3 10/L, with a leukoerythroblastic blood picture and 2%blasts, platelet count of 3873 10/L, and serum lactic dehydrogenase level of 1087U/L.BCR/ABLwas negative, and the JAK2 V617F mutation was found. Bone marrow cytogenetic study disclosed a normal 46,XY karyotype, and the marrow biopsy was typical of myelofibrosis. According to the International Prognostic Scoring System (IPSS), the patient had intermediate-2 risk PMF, because of age over 65 years and blood blasts $1%. Median survival of patients with intermediate-2 risk PMF is 4 years. Because the patient was asymptomatic and not eligible for allogeneic stem cell transplantation, shouldhe receive ruxolitinib to try toprolonghis survival?